Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women

Basit Öğe Kaydı
dc.authorid0000-0002-3166-9052en_US
dc.contributor.authorCoksuer, H.
dc.contributor.authorOzcura, F.
dc.contributor.authorOghan, F.
dc.contributor.authorHaliloglu, B.
dc.contributor.authorCoksuer, C.
dc.date.accessioned2024-07-12T21:45:42Z
dc.date.available2024-07-12T21:45:42Z
dc.date.issued2011en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractBackground Hormones may have an impact on the incidence and course of dry-eye syndrome, and also nasal obstruction, especially in postmenopausal women. The aim of this study was to investigate the effects of drospirenone 2 mg + estradiol 1 mg (Angeliq (R), Bayer AG, Berlin, Germany) on ocular functions and nasal airflow in postmenopausal women. Methods Thirty-four postmenopausal women were recruited for the study. A questionnaire on ocular surface disease index (OSDI) was administered; after routine ophthalmologic examination, tear film break-up time (TBUT) and Schirmer tests were performed. Intraocular pressure was measured with a Goldmann applanation tonometer. Nasal airflow resistance values were measured using rhinomanometry. Participants were submitted to oral daily treatment with drospirenone 2 mg + estradiol 1 mg. The duration of the study was 6 months and the participants were studied in the basal condition and after 6 months of therapy. Results The OSDI score and intraocular pressure were significantly higher before treatment than after treatment (p < 0.001); however, the results of the TBUT and Schimer test were significantly lower (p < 0.05). Rhinomanometric values were better during drospirenone 2 mg vertical bar estradiol 1 mg therapy than those observed at baseline (p < 0.001). Conclusions Oral daily treatment with drospirenone 2 mg + estradiol 1 mg reduces the risks for ocular diseases and nasal obstruction in postmenopausal women.en_US
dc.identifier.doi10.3109/13697137.2010.539724
dc.identifier.endpage487en_US
dc.identifier.issn1369-7137
dc.identifier.issue4en_US
dc.identifier.pmid21281244en_US
dc.identifier.scopus2-s2.0-79960444173en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage482en_US
dc.identifier.urihttps://dx.doi.org/10.3109/13697137.2010.539724
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7851
dc.identifier.volume14en_US
dc.identifier.wosWOS:000292779500012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofCLIMACTERICen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00509
dc.subjectHORMONE REPLACEMENT THERAPYen_US
dc.subjectDROSPIRENONEen_US
dc.subjectANGELIQen_US
dc.subjectDRY EYEen_US
dc.subjectOCULAR DISEASEen_US
dc.subjectNASAL AIRFLOWen_US
dc.titleEffects of estradiol-drospirenone on ocular and nasal functions in postmenopausal womenen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu